Skip to main navigation
Skip to content

Infinity Pharmaceuticals, Inc

Search
  • Toggle search form
  • Follow us on Twitter
  • Connect with us on LinkedIn

Investor Relations

  • Our Team
    • Mission Values
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Scientific Advisory Board
  • Our Development Program
    • Our Pipeline
    • Eganelisib
    • PI3K-Gamma
    • Selected Publications
    • Expanded Access
  • Investors/Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Executive Leadership
      • Board of Directors
      • Committees
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Analyst Coverage
    • Online Investor Kit
    • Information Request
  • Join Us
    • Our Community
    • Life at Infinity
    • Careers
    • Benefits
  • Contact Us

Press Releases

Infinity Pharmaceuticals, Inc. ASCO Genitourinary Cancers Symposium Call
Feb 11, 2021 at 7:30 AM EST
Listen to webcast

Keyword Search

  • Summary ToggleInfinity Announces Closing of $92 Million Public Offering of Common Stock
    February 18, 2021 at 8:30 AM EST
  • Summary ToggleInfinity Announces Pricing of $80 Million Public Offering of Common Stock
    February 12, 2021 at 8:30 AM EST
  • Summary ToggleInfinity Announces Proposed Public Offering of Common Stock
    February 11, 2021 at 4:01 PM EST
  • Summary ToggleInfinity Pharmaceuticals to Present at Upcoming BIO CEO & Investor Conference
    February 11, 2021 at 9:25 AM EST
  • Summary ToggleInfinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium
    February 11, 2021 at 7:15 AM EST
  • Summary ToggleInfinity Pharmaceuticals Announces Conference Call for the ASCO Genitourinary Cancers Symposium to Discuss Clinical Data from MARIO-275 Phase 2 Study
    February 10, 2021 at 4:05 PM EST
  • Summary ToggleInfinity Pharmaceuticals to Participate in B. Riley Securities Virtual Oncology Investor Conference
    January 15, 2021 at 8:35 AM EST
  • Summary ToggleInfinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO Genitourinary Cancers Symposium
    January 11, 2021 at 8:05 AM EST
  • Summary ToggleInfinity Pharmaceuticals to Participate in Three Investor Conferences This Month
    January 7, 2021 at 8:35 AM EST
  • Summary ToggleInfinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer
    January 6, 2021 at 9:11 AM EST

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last

Shareholder Tools

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Print

    Print

  • Email

    Email

Infinity Pharmaceuticals, Inc.

1100 Massachusetts Ave
Cambridge, MA 02138
617-453-1000

Terms and Conditions

  • Terms & Conditions
  • Privacy Policy
  • Forward Looking Statements
Connect With Us
  • Twitter
  • LinkedIn

Our Team

  • Our Team
    • Mission Values
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Scientific Advisory Board

Our Development Program

  • Our Development Program
    • Our Pipeline
    • Eganelisib
    • PI3K-Gamma
    • Selected Publications
    • Expanded Access

Investor / Media

  • Investors/Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Online Investor Kit
    • Information Request

Join Us

  • Join Us
    • Our Community
    • Life at Infinity
    • Careers
    • Benefits
© 2021 Infinity Pharmaceuticals, Inc. All Rights Reserved.